← investlyk

Dividend

Stocks tagged with the dividend theme.

Articles in this theme

QCOM

Qualcomm: a cheap, cash-rich chipmaker at 20x — and the most divided analyst coverage in this group

A 2-of-4 scorecard pairs cash-backed profits and a 21.6% free-cash-flow margin with revenue down about 3.5% and weakening price structure. The stock trades at 20x earnings, 30% below its high, and analysts are split — 42% Buy, 44% Hold, 14% Sell across 19 firms, with about 7% upside to a $193.97 target. Current price: $181.92.

semiconductorsdividend5g
MCD

McDonald's: a 3-of-4 franchise compounder in a price slump, with no analyst Sells

A 3-of-4 financial scorecard pairs a 44% operating margin and compounding equity with a stock 22% below its high and drifting lower. At 22x earnings, 24 analysts see about 32% upside to a $351.90 average target — 57% Buy, 43% Hold, no Sells. Current price: $267.18.

restaurantsdividendfranchise
SBUX

Starbucks: a turnaround priced at 79x earnings, with analysts barely above today's price

A 0-of-4 financial scorecard pairs cash-backed brand strength with negative free cash flow and a weak profit signal mid-turnaround. The stock trades at 79x earnings, 4% below its high, yet 20 analysts see only about 3.5% upside to a $108.27 average target — 57% Buy, 41% Hold. Current price: $104.06.

restaurantsdividendturnaround
CVX

Chevron: declining earnings and stalling timing — but three in four analysts still see double-digit upside

A 1-of-4 Financial Scorecard with a Value Pressure flag and 0-of-3 timing signals describe a business in a soft patch of the cycle. Yet 74% of 19 analysts rate it Buy, and the $203.28 average target sits about 14% above the price, even as the stock trades 17% below its high. Current price: $177.58.

integrated-energyoil-gasdividend
PFE

Pfizer: a cheap multiple and heavy free cash flow — and the most bearish analyst coverage in this group

A 2-of-4 scorecard pairs cash-backed profits and a 19.6% free-cash-flow margin with declining revenue and earnings. The stock trades at 19x earnings, 8% below its high — but only 23% of 12 analysts rate it Buy, against 60% Hold and 17% Sell. Current price: $25.92.

pharmadividendpatent-cliff